Watching the clock in glioblastoma
Authors:
Open Access
- 16 June 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (11) , 1932-1946
Abstract
Glioblastoma (GBM) is the most prevalent malignant primary brain tumor, accounting for 14.2% of all diagnosed tumors and 50.1% of all malignant tumors, and the median survival time is approximately 8 months irrespective of whether a patient receives treatment without significant improvement despite expansive research (Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neurooncology. 2022; 24(suppl 5):v1–v95.). Recently, important roles for the circadian clock in GBM tumorigenesis have been reported. Positive regulators of circadian-controlled transcription, brain and muscle ARNT-like 1 (BMAL1), and circadian locomotor output cycles kaput (CLOCK), are highly expressed also in GBM and correlated with poor patient prognosis. BMAL1 and CLOCK promote the maintenance of GBM stem cells (GSCs) and the establishment of a pro-tumorigenic tumor microenvironment (TME), suggesting that targeting the core clock proteins may augment GBM treatment. Here, we review findings that highlight the critical role the circadian clock plays in GBM biology and the strategies by which the circadian clock can be leveraged for GBM treatment in the clinic moving forward.Keywords
Funding Information
- National Cancer Institute (5R01CA238662, 5R35CA197718, 1R01CA268634)
- National Institute of Neurological Disorders and Stroke (1F31NS120654-01, 5R01NS103434)
- Charlie Teo Foundation
- Synchronicity Pharma
This publication has 96 references indexed in Scilit:
- Circadian Dbp Transcription Relies on Highly Dynamic BMAL1-CLOCK Interaction with E Boxes and Requires the ProteasomeMolecular Cell, 2012
- Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-βNature, 2012
- Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonistsNature, 2012
- Light treatment prevents fatigue in women undergoing chemotherapy for breast cancerSupportive Care in Cancer, 2011
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiologyNature, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- A Functional Genomics Strategy Reveals Rora as a Component of the Mammalian Circadian ClockNeuron, 2004